(19)
(11) EP 3 500 575 A2

(12)

(88) Date of publication A3:
01.11.2018

(43) Date of publication:
26.06.2019 Bulletin 2019/26

(21) Application number: 17841172.4

(22) Date of filing: 15.08.2017
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61P 37/00(2006.01)
A61P 35/00(2006.01)
 A61K 31/519(2006.01)
A61P 29/00(2006.01)
(86) International application number:
PCT/IB2017/054955
(87) International publication number:
WO 2018/033853 (22.02.2018 Gazette 2018/08)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 16.08.2016 WO PCT/CN2016/095510

(71) Applicant: BeiGene, Ltd.
Camana Bay, Grand Cayman KY1-1108 (KY)

(72) Inventors:
  • WANG, Zhiwei
    Beijing 102206 (CN)
  • GUO, Yunhang
    Beijing 102206 (CN)
  • SHI, Gongyin
    Beijing 102206 (CN)

(74) Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)

   


(54) CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF